Study Comparing Golcadomide and Rituximab with Other Treatments for Relapsed or Hard-to-Treat Follicular Lymphoma

Inclusion Criteria

• Diagnosed with follicular lymphoma (Grade 1, 2, or 3a) confirmed by a lab test.
• The lymphoma has returned after initial treatment or has not responded to the most recent treatment.
• Able to perform daily activities with little to no assistance (ECOG score 0-2).
• Have a PET scan showing active disease and at least one measurable tumor.
• Need treatment for lymphoma as determined by a doctor.
• Have had at least one previous treatment that included an anti-CD20 antibody (like Rituximab) and an alkylating agent (like Cyclophosphamide).
• Meet specific blood test requirements:
  • Neutrophil count of at least 1,000 cells/mm³.
  • Platelet count of at least 75,000 cells/mm³.
  • Hemoglobin level of at least 7.5 g/dL.
• Kidney function with an eGFR of at least 30 ml/min/1.73m².
• Liver function tests within specified limits, with allowances for liver involvement by lymphoma or Gilbert's syndrome.
• Adequate heart function for those receiving certain chemotherapy, with a heart pumping ability of at least 40%.

Exclusion Criteria

• Have a history or evidence of other types of lymphoma, such as Diffuse Large B-Cell Lymphoma or transformed Non-Hodgkin Lymphoma.
• Have follicular large cell lymphoma or duodenal-type follicular lymphoma.
• Have any significant medical, lab, or psychiatric conditions that would interfere with the study.
• Have conditions that make it difficult to interpret study data.
• Have or had lymphoma affecting the central nervous system.
• Have had a stroke or brain bleeding in the last 6 months.
• Have had a blood clot in the last month.
• Have a history of a specific brain infection called progressive multifocal leukoencephalopathy.
• Have any other type of lymphoma.
• Have persistent diarrhea or absorption issues despite treatment.
• Have had another cancer that hasn't been in remission for at least 3 years, except for non-invasive cancers.
• Are resistant to both chemotherapy and lenalidomide, with specific criteria for resistance.
• Other criteria as defined by the study protocol.